Cargando…

Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease

Increasing evidence suggests that Parkinson’s disease (PD) exhibits disparate spatial and temporal patterns of progression. Here we used a machine-learning technique—Subtype and Stage Inference (SuStaIn) — to uncover PD subtypes with distinct trajectories of clinical and neurodegeneration events. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Cheng, Wang, Linbo, Cheng, Wei, Lv, JinChao, Guan, Xiaoujun, Guo, Tao, Wu, Jingjing, Zhang, Wei, Gao, Ting, Liu, Xiaocao, Bai, Xueqin, Wu, Haoting, Cao, Zhengye, Gu, Luyan, Chen, Jingwen, Wen, Jiaqi, Huang, Peiyu, Xu, Xiaojun, Zhang, Baorong, Feng, Jianfeng, Zhang, Minming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344958/
https://www.ncbi.nlm.nih.gov/pubmed/37443179
http://dx.doi.org/10.1038/s41531-023-00556-3
_version_ 1785072977395580928
author Zhou, Cheng
Wang, Linbo
Cheng, Wei
Lv, JinChao
Guan, Xiaoujun
Guo, Tao
Wu, Jingjing
Zhang, Wei
Gao, Ting
Liu, Xiaocao
Bai, Xueqin
Wu, Haoting
Cao, Zhengye
Gu, Luyan
Chen, Jingwen
Wen, Jiaqi
Huang, Peiyu
Xu, Xiaojun
Zhang, Baorong
Feng, Jianfeng
Zhang, Minming
author_facet Zhou, Cheng
Wang, Linbo
Cheng, Wei
Lv, JinChao
Guan, Xiaoujun
Guo, Tao
Wu, Jingjing
Zhang, Wei
Gao, Ting
Liu, Xiaocao
Bai, Xueqin
Wu, Haoting
Cao, Zhengye
Gu, Luyan
Chen, Jingwen
Wen, Jiaqi
Huang, Peiyu
Xu, Xiaojun
Zhang, Baorong
Feng, Jianfeng
Zhang, Minming
author_sort Zhou, Cheng
collection PubMed
description Increasing evidence suggests that Parkinson’s disease (PD) exhibits disparate spatial and temporal patterns of progression. Here we used a machine-learning technique—Subtype and Stage Inference (SuStaIn) — to uncover PD subtypes with distinct trajectories of clinical and neurodegeneration events. We enrolled 228 PD patients and 119 healthy controls with comprehensive assessments of olfactory, autonomic, cognitive, sleep, and emotional function. The integrity of substantia nigra (SN), locus coeruleus (LC), amygdala, hippocampus, entorhinal cortex, and basal forebrain were assessed using diffusion and neuromelanin-sensitive MRI. SuStaIn model with above clinical and neuroimaging variables as input was conducted to identify PD subtypes. An independent dataset consisting of 153 PD patients and 67 healthy controls was utilized to validate our findings. We identified two distinct PD subtypes: subtype 1 with rapid eye movement sleep behavior disorder (RBD), autonomic dysfunction, and degeneration of the SN and LC as early manifestations, and cognitive impairment and limbic degeneration as advanced manifestations, while subtype 2 with hyposmia, cognitive impairment, and limbic degeneration as early manifestations, followed later by RBD and degeneration of the LC in advanced disease. Similar subtypes were shown in the validation dataset. Moreover, we found that subtype 1 had weaker levodopa response, more GBA mutations, and poorer prognosis than subtype 2. These findings provide new insights into the underlying disease biology and might be useful for personalized treatment for patients based on their subtype.
format Online
Article
Text
id pubmed-10344958
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-103449582023-07-15 Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease Zhou, Cheng Wang, Linbo Cheng, Wei Lv, JinChao Guan, Xiaoujun Guo, Tao Wu, Jingjing Zhang, Wei Gao, Ting Liu, Xiaocao Bai, Xueqin Wu, Haoting Cao, Zhengye Gu, Luyan Chen, Jingwen Wen, Jiaqi Huang, Peiyu Xu, Xiaojun Zhang, Baorong Feng, Jianfeng Zhang, Minming NPJ Parkinsons Dis Article Increasing evidence suggests that Parkinson’s disease (PD) exhibits disparate spatial and temporal patterns of progression. Here we used a machine-learning technique—Subtype and Stage Inference (SuStaIn) — to uncover PD subtypes with distinct trajectories of clinical and neurodegeneration events. We enrolled 228 PD patients and 119 healthy controls with comprehensive assessments of olfactory, autonomic, cognitive, sleep, and emotional function. The integrity of substantia nigra (SN), locus coeruleus (LC), amygdala, hippocampus, entorhinal cortex, and basal forebrain were assessed using diffusion and neuromelanin-sensitive MRI. SuStaIn model with above clinical and neuroimaging variables as input was conducted to identify PD subtypes. An independent dataset consisting of 153 PD patients and 67 healthy controls was utilized to validate our findings. We identified two distinct PD subtypes: subtype 1 with rapid eye movement sleep behavior disorder (RBD), autonomic dysfunction, and degeneration of the SN and LC as early manifestations, and cognitive impairment and limbic degeneration as advanced manifestations, while subtype 2 with hyposmia, cognitive impairment, and limbic degeneration as early manifestations, followed later by RBD and degeneration of the LC in advanced disease. Similar subtypes were shown in the validation dataset. Moreover, we found that subtype 1 had weaker levodopa response, more GBA mutations, and poorer prognosis than subtype 2. These findings provide new insights into the underlying disease biology and might be useful for personalized treatment for patients based on their subtype. Nature Publishing Group UK 2023-07-13 /pmc/articles/PMC10344958/ /pubmed/37443179 http://dx.doi.org/10.1038/s41531-023-00556-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhou, Cheng
Wang, Linbo
Cheng, Wei
Lv, JinChao
Guan, Xiaoujun
Guo, Tao
Wu, Jingjing
Zhang, Wei
Gao, Ting
Liu, Xiaocao
Bai, Xueqin
Wu, Haoting
Cao, Zhengye
Gu, Luyan
Chen, Jingwen
Wen, Jiaqi
Huang, Peiyu
Xu, Xiaojun
Zhang, Baorong
Feng, Jianfeng
Zhang, Minming
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
title Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
title_full Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
title_fullStr Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
title_full_unstemmed Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
title_short Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
title_sort two distinct trajectories of clinical and neurodegeneration events in parkinson’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344958/
https://www.ncbi.nlm.nih.gov/pubmed/37443179
http://dx.doi.org/10.1038/s41531-023-00556-3
work_keys_str_mv AT zhoucheng twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT wanglinbo twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT chengwei twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT lvjinchao twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT guanxiaoujun twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT guotao twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT wujingjing twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT zhangwei twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT gaoting twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT liuxiaocao twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT baixueqin twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT wuhaoting twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT caozhengye twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT guluyan twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT chenjingwen twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT wenjiaqi twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT huangpeiyu twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT xuxiaojun twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT zhangbaorong twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT fengjianfeng twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease
AT zhangminming twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease